1. Home
  2. BAP vs UTHR Comparison

BAP vs UTHR Comparison

Compare BAP & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Credicorp Ltd.

BAP

Credicorp Ltd.

HOLD

Current Price

$320.57

Market Cap

26.4B

Sector

Finance

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$523.84

Market Cap

23.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BAP
UTHR
Founded
1889
1996
Country
Peru
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.4B
23.9B
IPO Year
1997
1999

Fundamental Metrics

Financial Performance
Metric
BAP
UTHR
Price
$320.57
$523.84
Analyst Decision
Buy
Buy
Analyst Count
5
14
Target Price
$291.60
$531.79
AVG Volume (30 Days)
355.7K
497.9K
Earning Date
02-12-2026
04-29-2026
Dividend Yield
3.35%
N/A
EPS Growth
N/A
13.07
EPS
N/A
27.86
Revenue
N/A
$1,483,300,000.00
Revenue This Year
$22.58
$7.05
Revenue Next Year
$8.84
$13.30
P/E Ratio
$12.91
$18.93
Revenue Growth
N/A
2.38
52 Week Low
$165.51
$266.98
52 Week High
$380.20
$548.12

Technical Indicators

Market Signals
Indicator
BAP
UTHR
Relative Strength Index (RSI) 41.70 56.10
Support Level $319.35 $464.92
Resistance Level $360.83 $542.66
Average True Range (ATR) 11.40 13.44
MACD -1.91 0.51
Stochastic Oscillator 21.14 70.23

Price Performance

Historical Comparison
BAP
UTHR

About BAP Credicorp Ltd.

Credicorp Ltd is a Peruvian financial services company. It operates in four business lines, including Universal Banking, Insurance and Pensions, Microfinance, and Investment Management & Advisory. Its subsidiaries include Banco de Credito del Peru, Prima AFP, and Credicorp Capital. Geographically, the company operates in Peru, Colombia, Bolivia, Chile, Panama, the USA, and Mexico; the majority of its revenue is generated from Peru.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: